Arsenic Trioxide Causes Redistribution of Cell Cycle, Caspase Activation, and GADD Expression in Human Colonic, Breast, and Pancreatic Cancer Cells

Arsenic trioxide is valuable for treatment of promyelocytic leukemia, but less attention has been paid to its therapeutic potential for other cancers. In this study, the effects of arsenic trioxide were tested in human pancreatic (AsPC-1), colonic (HT-29), and breast (MCF-7) cancer cells. In all three cancer cell lines, arsenic trioxide inhibited proliferation in a concentration and time-dependent manner, as measured by 3H-methyl thymidine incorporation and cell counting. Coincident with inhibition of growth, arsenic trioxide induced marked morphologic changes, including reduced cytoplasmic volume, membrane blebbing, and nuclear condensation consistent with apoptosis. Propidium iodide DNA staining at 24 hours revealed cell cycle arrest in the G0/G1 phase and an increase in the S phase, while at 72 hr there was G2/M phase arrest with a marked increase in the sub-G0/G1, apoptotic cell population. The DNA fragmentation induced by arsenic trioxide was confirmed by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay in all cell lines. Western blot analysis revealed activation of caspase -3, -7, and -9 by arsenic trioxide. Caspase-3 activity was confirmed by demonstrating cleavage of its downstream target, poly ADP-ribose polymerase (PARP). Expression of the antiapoptosis protein, Bcl-2, was time-dependently decreased. In contrast, arsenic trioxide markedly enhanced the expression of the p21 protein, GADD45 and GADD153, in a time-dependent manner. These findings suggest that arsenic trioxide has potential as a therapeutic agent for these cancers.

[1]  S. Waxman,et al.  History of the development of arsenic derivatives in cancer therapy. , 2001, The oncologist.

[2]  T. Sakai,et al.  Involvement of the Oct-1 regulatory element of the gadd45 promoter in the p53-independent response to ultraviolet irradiation. , 2001, Cancer research.

[3]  S. Waxman,et al.  Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells. , 2001, Leukemia research.

[4]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[5]  R. Gallagher,et al.  Co-biomodulation with arsenic trioxide in multiple myeloma. , 2001, Leukemia research.

[6]  S. Shelley,et al.  NR8383 alveolar macrophage toxic growth arrest by hydrogen peroxide is associated with induction of growth-arrest and DNA damage-inducible genes GADD45 and GADD153. , 1997, Toxicology and applied pharmacology.

[7]  Jay X. Tang,et al.  Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. , 1997, Science.

[8]  C. Peschle,et al.  Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. , 1998, Journal of the National Cancer Institute.

[9]  Y. Y. Lee,et al.  Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. , 1999, Biochemical and biophysical research communications.

[10]  S. Rafii,et al.  Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. , 2000, Blood.

[11]  P. Pandolfi,et al.  Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. , 1998, The New England journal of medicine.

[12]  C. Forkner,et al.  ARSENIC AS A THERAPEUTIC AGENT IN CHRONIC MYELOGENOUS LEUKEMIA: PRELIMINARY REPORT , 1931 .

[13]  K. Antman,et al.  Introduction: the history of arsenic trioxide in cancer therapy. , 2001, The oncologist.

[14]  P. Pandolfi,et al.  Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. , 1998, Blood.

[15]  H. Gisslinger,et al.  Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? , 2001, British journal of haematology.

[16]  N. Thornberry,et al.  The Caspase-3 Precursor Has a Cytosolic and Mitochondrial Distribution: Implications for Apoptotic Signaling , 1998, The Journal of cell biology.

[17]  Zhen-yi Wang,et al.  Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. , 2001, Seminars in hematology.

[18]  W. Au,et al.  Arsenic trioxide‐ and idarubicin‐induced remissions in relapsed acute promyelocytic leukaemia: Clinicopathological and molecular features of a pilot study , 2001, American journal of hematology.

[19]  K. Jan,et al.  Calcium-dependent nitric oxide production is involved in arsenite-induced micronuclei. , 1998, Mutation research.

[20]  Y. Akao,et al.  Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro , 1999, FEBS letters.

[21]  S. Soignet,et al.  Risk/benefit profile of arsenic trioxide. , 2001, The oncologist.

[22]  G. Chen,et al.  Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. , 2001, Seminars in hematology.

[23]  E. Faustman,et al.  Induction of growth arrest and DNA damage-inducible genes Gadd45 and Gadd153 in primary rodent embryonic cells following exposure to methylmercury. , 1997, Toxicology and applied pharmacology.

[24]  E. Cao,et al.  Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. , 1999, European journal of cancer.

[25]  C. Niu,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. , 1997, Blood.

[26]  A. Fornace,et al.  Evidence for distinct kinase-mediated pathways in gadd gene responses. , 1998, Biochemical pharmacology.

[27]  Wei Tang,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.

[28]  J. Shen,et al.  The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. , 2000, International journal of molecular medicine.

[29]  G. Hannon,et al.  The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA , 1994, Nature.

[30]  G. Endo,et al.  Metabolites of Arsenic Induced Tetraploids and Mitotic Arrest in Cultured Cells , 1997, Archives of environmental contamination and toxicology.

[31]  S. Yuen,et al.  Arsenic trioxide induces apoptosis in human gastric cancer cells through up‐regulation of P53 and activation of caspase‐3 , 2001, International journal of cancer.

[32]  M. Fu,et al.  Arsenic trioxide induces apoptosis of HPV16 DNA‐immortalized human cervical epithelial cells and selectively inhibits viral gene expression , 1999, International journal of cancer.

[33]  J. Shen,et al.  Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro. , 1999, International journal of molecular medicine.

[34]  C. Sezgin,et al.  Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  J. Lyons,et al.  Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. , 2000, Neoplasia.

[36]  N. Munshi,et al.  Arsenic trioxide: an emerging therapy for multiple myeloma. , 2001, The oncologist.